Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Evid Based Complement Alternat Med
2018 Jan 01;2018:5080764. doi: 10.1155/2018/5080764.
Show Gene links
Show Anatomy links
An Investigation of the Prescription Patterns of Chinese Herbal Products for Chronic Glomerulonephritis Patients: A Hospital-Based Cross-Sectional Study.
Chen W
,
Chen HY
,
Yang YH
,
Yang SH
,
Yang CW
,
Wu YH
,
Chen JL
.
???displayArticle.abstract???
Chronic kidney disease (CKD) has a high incidence and prevalence worldwide, and chronic glomerulonephritis (CGN) is one of the main causes of CKD. Therefore, it is important to diagnose and treat CGN early. The purpose of this study is to analyze the prescription patterns and frequencies of Chinese herbal products (CHPs) for CGN by using a hospital-based database from the Chang Gung Memorial Hospital (CGMH), a large, tertiary hospital system in Taiwan, and to evaluate the safety and possible efficacy of CHPs by blood test. The International Classification of Disease Ninth Revision (ICD-9) code 582 was used to identify patients with CGN. From 2004 to 2015, a total of 54726 CHP prescriptions for CGN were provided. Association rule mining was used to analyze the prevalent of CHP combination patterns in treating CGN. Jia-Wei-Xiao-Yao-San (JWXYS) and Gorgon (Euryale feroxSalisb.) were the most frequently prescribed herbal formula (HF) and single herb (SH), respectively. The most frequently prescribed combination of CHPs was that of JWXYS with Bu-Yang-Huan-Wu-Tang (BYHWT) in CGMH. In statistical, the level of eGFR in Stage 3a and 3b group was increasing after treatment in 6 and 12 months and might not cause the renal function to worsen within 12-month treatments. To the best of our knowledge, this is the first pharmacoepidemiological study to review CHP treatments for CGN. However, additional studies and clinical trials are needed to provide data on the safety and efficacy of these CHPs.
Figure 1.
Distribution of Chinese herbal products (CHPs) counts per prescription. TCM doctors commonly prescribe 5 CHPs per prescription and, on average, each prescription contained 6.04 CHPs for chronic glomerulonephritis patients. A single CHP in one prescription is the least frequent.
Figure 2.
Social network analysis on associations between commonly used CHPs for CGN. JWXYS was the center of the CHPs network prescribed for CGN and became the core treatment for CGN. Larger circle represents higher frequency of prescription, and thicker connection line represents more common combination.
Figure 3. The level ofeGFR in CGN patients with CHPs. Data was collected from Chang Gung Research Database. Chronic glomerulonephritis patients were selected as described under materials and methods (eGFR n =386). Figure 3 is the eGFR change according to the eGFR level before the initial treatment. All groups showed a significant upward trend within 6 months after CHPs use. Only the Stage 3a and 3b groups continued to increase significantly within 12 months.
Andrassy,
Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.
2013, Pubmed
Andrassy,
Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.
2013,
Pubmed
Chen,
[Inhibitory effects of pretreatment with Buyanghuanwu decoction on inflammatory cytokine expressions in the kidneys of rats after induction of brain death].
2009,
Pubmed
Chen,
Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan.
2015,
Pubmed
Chiang,
Herb-drug pharmacokinetic interaction of a traditional chinese medicine jia-wei-xiao-yao-san with 5-Fluorouracil in the blood and brain of rat using microdialysis.
2015,
Pubmed
Cui,
Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage.
2015,
Pubmed
Fei,
Salvia miltiorrhiza Bunge (Danshen) extract attenuates permanent cerebral ischemia through inhibiting platelet activation in rats.
2017,
Pubmed
Gao,
A Chinese herbal decoction, Danggui Buxue Tang, prepared from Radix Astragali and Radix Angelicae Sinensis stimulates the immune responses.
2006,
Pubmed
Hedayati,
Epidemiology, diagnosis, and management of depression in patients with CKD.
2009,
Pubmed
Hou,
Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats.
2016,
Pubmed
Hsu,
Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study.
2014,
Pubmed
Hu,
In vitro anti-fibrotic activities of herbal compounds and herbs.
2009,
Pubmed
Jha,
Chronic kidney disease: global dimension and perspectives.
2013,
Pubmed
Kanai,
Study of sokei-kakketu-to (shu-jing-huo-xue-tang) in adjuvant arthritis rats.
2003,
Pubmed
Li,
Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae.
2010,
Pubmed
Li,
Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
2014,
Pubmed
Li,
Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy.
2011,
Pubmed
Liao,
[Effect of Buyanghuanwu decoction on neuronal nitric oxide synthase expression after permanent focal cerebral ischemia in rats].
2004,
Pubmed
Lin,
Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease.
2015,
Pubmed
Lin,
Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility.
2015,
Pubmed
Liu,
Herb-drug interactions involving drug metabolizing enzymes and transporters.
2011,
Pubmed
Luo,
Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients.
2013,
Pubmed
Ma,
Attenuation of renal ischemic reperfusion injury by salvianolic acid B via suppressing oxidative stress and inflammation through PI3K/Akt signaling pathway.
2017,
Pubmed
MacKinnon,
Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
2006,
Pubmed
Min,
Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential.
2016,
Pubmed
Nagler,
Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).
2012,
Pubmed
Park,
Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats.
2014,
Pubmed
Qu,
[Protective effect of Buyanghuanwu Tang on cultured rat cortical neurons against hypoxiainduced apoptosis].
2002,
Pubmed
Saruwatari,
Effects of Seijo-bofu-to, a traditional Japanese herbal medicine containing furanocoumarin derivatives, on the drug-metabolizing enzyme activities in healthy male volunteers.
2014,
Pubmed
Shahzad,
The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease.
2016,
Pubmed
Shu,
Anti-hypersensitivity effects of Shu-jing-huo-xue-tang, a Chinese herbal medicine, in CCI-neuropathic rats.
2010,
Pubmed
Su,
Effects of unprocessed versus vinegar-processed Schisandra chinensis on the activity and mRNA expression of CYP1A2, CYP2E1 and CYP3A4 enzymes in rats.
2013,
Pubmed
Tseng,
The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death.
2014,
Pubmed
Wang,
Assessment of the renal protection and hepatotoxicity of rhubarb extract in rats.
2009,
Pubmed
Wang,
Du-Huo-Ji-Sheng-Tang and its active component Ligusticum chuanxiong promote osteogenic differentiation and decrease the aging process of human mesenchymal stem cells.
2017,
Pubmed
Wen,
All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.
2008,
Pubmed
Wenjin,
Protective Effect of Gentianine, a compound from Du Huo Ji Sheng Tang, against Freund's Complete Adjuvant-Induced Arthritis in Rats.
2017,
Pubmed
Yasui,
Changes in circulating cytokine levels in midlife women with psychological symptoms with selective serotonin reuptake inhibitor and Japanese traditional medicine.
2009,
Pubmed
Zhang,
Astragalus (a traditional Chinese medicine) for treating chronic kidney disease.
2014,
Pubmed
Zhao,
[Effect of BuYangHuanWu recipe on cerebral microcirculation in gerbils with ischemia-reperfusion].
2010,
Pubmed
Zhou,
Effects of buyang huanwu decoction on ventricular remodeling and differential protein profile in a rat model of myocardial infarction.
2012,
Pubmed
Zhu,
Emodin inhibits extracellular matrix synthesis by suppressing p38 and ERK1/2 pathways in TGF-β1-stimulated NRK-49F cells.
2011,
Pubmed
